 The experimental drug, RM-1929, is a parental formulation consisting of a chemical conjugate of the dye IR700 with the FDA approved antibody, Erbitux Cetuximab, that targets EGFR receptors EGFR is a cancer expressed protein, a cancer antigen. EGFR is highly expressed in squamous cell carcinomas of the head and neck HNSCC. It is expected that systemic administration of RM-1929 will lead to tumor accumulation and binding to EGFR expressed at cancer cells. It is expected that treatment with RM-1929 and Photoimmunotherapy can lead to the selective destruction of the HNSCC cancer cells and provide an effective therapy to manage the disease. 